"we’re... underway with our own Brilacidin oral formulation efforts to treat more extensive forms of IBD. We currently are utilizing sophisticated, controlled-release tablet technology to enable targeted delivery of oral Brilacidin in the colon, with in-human testing anticipated to start as soon as year-end."

And there you have it. This deal give the company the money to go full speed ahead (they're undoubtedly already well on the way) for the oral formulation. THAT'S where the true blockbuster potential is -- massive, massive market.

And here's the thing -- Alfasigma has the right of first refusal, but the company is in the driver's seat since IPIX is the one developing it. And who knows -- when (disclaimer: "if" hahaha) the results look good, it's possible the company can strike another deal with Alfasigma for the oral formulation early on in the clinical trials.

This also gives the company the money to go ahead with the Brilacidin-OM trials.